Русский / English
Enter the query
News
Press Center
phone: +7 495 785 29 07
fax: +7 499 230 32 94
press@interros.ru
Contacts
The Russian tokenization platform Atomyze, where Vladimir Potanin's Interros is one of the investors, received the operator status of an information system for managing digital financial assets (DFA) from the Central Bank. In accordance with the recently adopted law on DFA in Russia, the regulator granted the rights to issue and circulate DFA in exchange for Russian rubles, as well as to store DFA, maintain a register of holders and to support electronic accounts and channels for servicing DFA holders. More Topics Atomyze / Vladimir Potanin / Interros / DFA
Building on the success of Rosa Khutor resort, the $1 bln project will bring quality hotels and rehabilitation facilities, new skiing tracks for over a million of visitors per year while creating thousands of new jobs More Topics Interros / VEB.RF / Vasta Discovery / Sochi
22.07.2020
A Russian original medication called Polyoxidonium® by Petrovax, a pharmaceutical company affiliated to the Interros Group, has passed the first phase of an international clinical trial for its effectiveness and safety for COVID-19 treatment.
More Topics Petrovax Pharm
17.04.2020
Polyoxidonium (azoximer bromide) - the Russian original drug produced by Petrovax-  was approved by the Ministry of Health of the Russian Federation for conducting an international clinical trial for the treatment of COVID-19.
More Topics Petrovax Pharm
23.03.2020
The Foundation is now announcing the launch of new large-scale initiatives to help non-profits and their beneficiaries to survive the next few months
More Topics COVID-19 / donations / coronavirus / Vladimir Potanin